2.89
price up icon3.21%   0.09
 
loading
Schlusskurs vom Vortag:
$2.80
Offen:
$2.8
24-Stunden-Volumen:
145
Relative Volume:
0.01
Marktkapitalisierung:
$26.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.87M
KGV:
-0.1469
EPS:
-19.67
Netto-Cashflow:
$-47.63M
1W Leistung:
+11.15%
1M Leistung:
+6.64%
6M Leistung:
-12.42%
1J Leistung:
-39.79%
1-Tages-Spanne:
Value
$2.80
$2.80
1-Wochen-Bereich:
Value
$2.45
$3.25
52-Wochen-Spanne:
Value
$2.30
$4.94

Polypid Ltd Stock (PYPD) Company Profile

Name
Firmenname
Polypid Ltd
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
61
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-13
Name
Neueste SEC-Einreichungen
Name
PYPD's Discussions on Twitter

Vergleichen Sie PYPD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PYPD
Polypid Ltd
2.80 26.50M 0 -23.87M -47.63M -19.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
500.26 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.36 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
649.65 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
258.08 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
256.14 26.40B 3.81B -644.79M -669.77M -6.24

Polypid Ltd Stock (PYPD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-28 Eingeleitet Rodman & Renshaw Buy
2021-09-14 Eingeleitet JMP Securities Mkt Outperform
2021-07-30 Eingeleitet Cantor Fitzgerald Overweight
2020-11-24 Hochstufung Raymond James Outperform → Strong Buy
2020-08-10 Eingeleitet Alliance Global Partners Buy
2020-07-21 Eingeleitet BMO Capital Markets Outperform
2020-07-21 Eingeleitet Barclays Overweight
2020-07-21 Eingeleitet Raymond James Outperform
Alle ansehen

Polypid Ltd Aktie (PYPD) Neueste Nachrichten

pulisher
May 01, 2025

PolyPid Ltd. (NASDAQ:PYPD) Short Interest Update - Defense World

May 01, 2025
pulisher
Apr 29, 2025

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025 - GlobeNewswire

Apr 29, 2025
pulisher
Apr 29, 2025

PolyPid Q1 2025 Earnings Preview: Surgical Outcomes Biopharma Reports May 14 - Stock Titan

Apr 29, 2025
pulisher
Apr 23, 2025

Reviewing Baxter International (NYSE:BAX) and PolyPid (NASDAQ:PYPD) - Defense World

Apr 23, 2025
pulisher
Apr 22, 2025

PolyPid to Participate in The Citizens Life Sciences Conference - GlobeNewswire

Apr 22, 2025
pulisher
Apr 22, 2025

PolyPid to Reveal Next-Gen Surgical Innovation Pipeline at Elite Citizens Life Sciences Conference - Stock Titan

Apr 22, 2025
pulisher
Apr 19, 2025

Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Declines By 25.9% - Defense World

Apr 19, 2025
pulisher
Apr 17, 2025

What is HC Wainwright’s Estimate for PolyPid Q1 Earnings? - Defense World

Apr 17, 2025
pulisher
Apr 16, 2025

What is HC Wainwright’s Forecast for PolyPid Q1 Earnings? - Defense World

Apr 16, 2025
pulisher
Apr 15, 2025

H.C. Wainwright maintains Buy on PolyPid stock with $11 target - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

PolyPid’s (PYPD) Buy Rating Reaffirmed at HC Wainwright - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

H.C. Wainwright maintains Buy on PolyPid stock with $11 target By Investing.com - Investing.com Canada

Apr 14, 2025
pulisher
Apr 07, 2025

PolyPid stock touches 52-week low at $2.32 amid market challenges By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

PolyPid stock touches 52-week low at $2.32 amid market challenges - Investing.com Australia

Apr 07, 2025
pulisher
Apr 03, 2025

Surgical Site Infections Clinical and Non-Clinical Studies, - openPR.com

Apr 03, 2025
pulisher
Mar 24, 2025

Barclays Reaffirms Their Hold Rating on PolyPid (PYPD) - The Globe and Mail

Mar 24, 2025
pulisher
Mar 23, 2025

Comparing Beta Bionics (NASDAQ:BBNX) and PolyPid (NASDAQ:PYPD) - Defense World

Mar 23, 2025
pulisher
Mar 11, 2025

PolyPid Completes Enrollment in Phase 3 Trial for Surgical Infection Prevention - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

PolyPid Announces Successful Completion of Enrollment in - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

PolyPid Announces Successful Completion Of Enrollment In Phase 3 Shield II Trial Of D-Plex100 For The Prevention Of Abdominal Colorectal Surgical Site Infections - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections - Yahoo

Mar 11, 2025
pulisher
Mar 10, 2025

Critical Survey: Nyxoah (NASDAQ:NYXH) vs. PolyPid (NASDAQ:PYPD) - Defense World

Mar 10, 2025
pulisher
Mar 06, 2025

PolyPid (NASDAQ:PYPD) Stock Price Up 0.7% – Should You Buy? - Defense World

Mar 06, 2025
pulisher
Mar 03, 2025

PolyPid to Participate in the 37th Annual ROTH Conference - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

PolyPid Fireside Chat at ROTH Conference: What New Surgical Innovations Will Management Reveal? - StockTitan

Mar 03, 2025
pulisher
Feb 27, 2025

Polypid Ltd to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

PolyPid Ltd. to Present at the Q1 Investor Summit Virtual Conference on March 11th, 2025 - The Globe and Mail

Feb 27, 2025
pulisher
Feb 13, 2025

PolyPid Ltd. Earnings Call Highlights Promising Prospects - TipRanks

Feb 13, 2025
pulisher
Feb 13, 2025

PolyPid Ltd. (NASDAQ:PYPD) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 13, 2025
pulisher
Feb 12, 2025

PolyPid Ltd. Reports Positive Trial Progress and Financial Outlook - TipRanks

Feb 12, 2025
pulisher
Feb 12, 2025

PolyPid targets SHIELD II trial completion with top-line results in Q2 2025 - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

PolyPid Updates: New Board Appointment and SHIELD II Trial Progress - TipRanks

Feb 12, 2025
pulisher
Feb 12, 2025

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results - The Manila Times

Feb 12, 2025
pulisher
Feb 12, 2025

PolyPid's Phase 3 Trial Nears Completion: Key Financial Updates Reveal Path to Critical Q2 2025 Results - StockTitan

Feb 12, 2025
pulisher
Feb 07, 2025

PolyPid (PYPD) to Release Earnings on Wednesday - Defense World

Feb 07, 2025
pulisher
Jan 31, 2025

Head-To-Head Contrast: PolyPid (NASDAQ:PYPD) versus OraSure Technologies (NASDAQ:OSUR) - Defense World

Jan 31, 2025
pulisher
Jan 31, 2025

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire

Jan 31, 2025
pulisher
Jan 30, 2025

Surgical Outcomes Pioneer PolyPid Takes Center Stage at Major Healthcare Conference - StockTitan

Jan 30, 2025
pulisher
Jan 30, 2025

PolyPid Ltd. to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Nasdaq

Jan 30, 2025
pulisher
Jan 30, 2025

PolyPid (NASDAQ:PYPD) Stock Rating Upgraded by RODMAN&RENSHAW - Defense World

Jan 30, 2025
pulisher
Jan 29, 2025

PolyPid to Report Fourth Quarter and Full-Year 2024 - GlobeNewswire

Jan 29, 2025
pulisher
Jan 29, 2025

Major Surgical Innovation Updates Expected: PolyPid Sets Critical Q4 Earnings Date - StockTitan

Jan 29, 2025

Finanzdaten der Polypid Ltd-Aktie (PYPD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$72.79
price up icon 0.11%
$21.39
price up icon 2.27%
$32.67
price up icon 0.49%
$29.24
price up icon 18.78%
$105.61
price up icon 3.06%
biotechnology ONC
$256.40
price up icon 0.63%
Kapitalisierung:     |  Volumen (24h):